A61K 38/2228
Corticotropin releasing factor [crf]
Official title: {Corticotropin releasing factor [CRF] (Urotensin)}
A61K38/2228 (Corticotropin releasing factor [crf]) appears on 47 US grants and 69 published applications in this corpus.
Search patents in A61K- Granted patents
- 47
- Published applications
- 69
- Assignees
- 36
- Inventors
- 131
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 4 |
| 2004 | 3 | 2 |
| 2005 | 1 | 0 |
| 2006 | 1 | 1 |
| 2007 | 0 | 2 |
| 2008 | 2 | 4 |
| 2009 | 0 | 3 |
| 2010 | 2 | 5 |
| 2011 | 1 | 2 |
| 2012 | 0 | 4 |
| 2013 | 1 | 5 |
| 2014 | 3 | 4 |
| 2015 | 0 | 3 |
| 2016 | 3 | 4 |
| 2017 | 2 | 4 |
| 2018 | 1 | 5 |
| 2019 | 1 | 6 |
| 2020 | 1 | 1 |
| 2021 | 4 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 3 |
| 2024 | 3 | 0 |
| 2025 | 3 | 3 |
| 2026 | 2 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Kits for preparing and delivering purified corticotropin15 Sep 2026US 12,734,217 B1ANI Pharmaceuticals, Inc.
- CRF2 receptor agonists and their use in therapy14 Jul 2026US 12,679,878 B2Sanofi
- Kits for preparing and delivering purified corticotropin14 Oct 2025US 12,440,542 B1ANI Pharmaceuticals, Inc.
- Kits for preparing and delivering purified corticotropin10 Jun 2025US 12,324,787 B1ANI Pharmaceuticals, Inc.
- Methods for storing and warming purified corticotropin compositions25 Feb 2025US 12,233,105 B1ANI Pharmaceuticals, Inc.
- Improved methods of treating diseases resulting from a maladapted stress response16 Oct 2025US 2025/0319161 A1Cortene Inc.
- Crf2 receptor agonists and their use in therapy31 Jul 2025US 2025/0243255 A1Sanofi
- Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor27 Feb 2025US 2025/0064896 A1Maison Amori oqvpo LLC
- Methods, devices, and systems for treating lens protein aggregation diseases5 Oct 2023US 2023/0310380 A1
- Methods, devices, and systems for treating lens protein aggregation diseases5 Oct 2023US 2023/0310471 A1
Most cited
By later US patents
- Method of inhibiting inflammatory response29US 4,801,612 AThe Regents of the University of California · 1989
- Treatment for irritable bowel syndrome26US 5,236,901 AResearch Corporation Technologies, Inc. · 1993
- Treatment to reduce edema for brain and musculature injuries20US 5,137,871 AThe Regents of the University of California · 1992
- Treatment of cancer with peptide analog of bombesin, GRP, litorin or neuromedin18US 5,217,955 ABiomeasure, Inc. · 1993
- Isolated nucleic acid encoding corticotropin-releasing factor.sub.2 receptors16US 5,786,203 ANeurocrine Biosciences, Inc. · 1998